Synthesis, evaluation and molecular docking of prolyl-fluoropyrrolidine derivatives as dipeptidyl peptidase IV inhibitors

Chemical Biology and Drug Design

Volumn 82, Issue 2, 2013, Pages 156-166

  Sharma, Mani ^a   Gupta, Monica ^a   Singh, Divya ^a   Kumar, Manoj ^b   Kaur, Punit ^b  

^a DELHI INSTITUTE OF PHARMACEUTICAL SCIENCES AND RESEARCH   (India)

^b ALL INDIA INSTITUTE OF MEDICAL SCIENCES   (India)

Author keywords

Diabetes; Dipeptidyl peptidase IV; Molecular docking; Prolyl fluoropyrrolidine

Indexed keywords

(3 FLUORO PYRROLIDIN 1 YL) [1 (2 PIPERIDIN 1 YL ETHYL)PYRROLIDIN 2 YL] METHANONE; (3 FLUOROPYRROLIDIN 1 YL) (PYRROLIDIN 2 YL)METHANONE; 1 AZEPAN 1 YL 2 [2 (3 FLUORO PYRROLIDINE 1 CARBONYL) PYRROLIDIN 1 YL] ETHANONE; 2 [2 (3 FLUORO PYRROLIDINE 1 CARBONYL) PYRROLIDIN 1 YL] 1 (4 PYRIMIDIN 2 YL PIPERAZIN YL) ETHANONE; 2 [2 (3 FLUORO PYRROLIDINE 1 CARBONYL) PYRROLIDIN 1YL] 1 (4 PYRIDIN 2 YL PIPERAZIN 1 YL) ETHANONE; 2 [2 [(3 FLUOROPYRROLIDIN 1 YL)CARBONYL]PYRROLIDIN 1 YL] 1 (PIPERIDIN 1 YL)ETHANONE; 2 [2 [(3 FLUOROPYRROLIDIN 1 YL)CARBONYL]PYRROLIDIN 1 YL] 1 (PYRROLIDIN 1 YL)ETHANONE; [1 (2 DIETHYLAMINO ETHYL) PYRROLIDIN 2 YL] (3 FLUOROPYRROLIDIN 1 YL) METHANONE; [1 [2 (DIMETHYLAMINO)ETHYL]PYRROLIDIN 2 YL](3 FLUOROPYRROLIDIN 1 YL)METHANONE; ACETAMIDE; ANTIDIABETIC AGENT; DIPEPTIDYL PEPTIDASE IV INHIBITOR; GLUCOSE; PIPERAZINE; PYRROLIDINE DERIVATIVE; UNCLASSIFIED DRUG; VILDAGLIPTIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIDIABETIC ACTIVITY; ARTICLE; CHEMICAL MODIFICATION; CONTROLLED STUDY; CRYSTAL STRUCTURE; DRUG BINDING SITE; DRUG RECEPTOR BINDING; DRUG SCREENING; DRUG SYNTHESIS; ENZYME INHIBITION; GLUCOSE BLOOD LEVEL; GLUCOSE TOLERANCE TEST; HYDROGEN BOND; IC 50; IN VITRO STUDY; IN VIVO STUDY; MALE; MOLECULAR DOCKING; NONHUMAN; ORAL GLUCOSE TOLERANCE TEST; PRIORITY JOURNAL; RAT; STREPTOZOCIN DIABETES; STRUCTURE ACTIVITY RELATION;

DIABETES; DIPEPTIDYL PEPTIDASE IV; MOLECULAR DOCKING; PROLYL-FLUOROPYRROLIDINE;

ANIMALS; DIABETES MELLITUS, EXPERIMENTAL; DIPEPTIDYL PEPTIDASE 4; DIPEPTIDYL-PEPTIDASE IV INHIBITORS; HALOGENATION; HUMANS; HYPOGLYCEMIC AGENTS; MALE; MODELS, MOLECULAR; MOLECULAR DOCKING SIMULATION; PYRROLIDINES; RATS; RATS, WISTAR;

RATTUS;

EID: 84880720439     PISSN: 17470277     EISSN: 17470285     Source Type: Journal    
DOI: 10.1111/cbdd.12142     Document Type: Article

References (25)

1. Lambeir A.M., Durnx C., Scharpe S., Meester I. (2003) Dipeptidylpeptidase IV from bench to bedside: an update on structural properties, functions, and clinical aspects of the enzyme DPP IV. Crit Rev Clin Lab Sci;40:209-294.
2. Mentlein R. (1999) Dipeptidyl-peptidase IV (CD26)-role in the inactivation of regulatory peptides. Regul Pept;85:9-24.
3. Verspohl E.J. (2009) Novel therapeutics for type 2 diabetes: incretin hormone mimetics (glucagons-like peptide-1 receptor agonists) and dipeptidyl peptidase-4 inhibitors. Pharmacol Ther;124:113-138.
4. Mest H.J., Mentlein R. (2005) Dipeptidyl peptidase inhibitors as new drugs for the treatment of type 2 diabetes. Diabetologia;48:616-620.
5. Chyan Y.J., Chuang L.M. (2007) Dipeptidyl peptidase-IV inhibitors: an evolving treatment for type 2 diabetes from the incretin concept. Recent Pat Endocr Metab Immune Drug Discov;1:15-24.
6. Yoshida T., Sakashita H., Akahoshi F., Hayashi Y. (2007) [(S)-γ-(4-Aryl-1-piperazinyl)-l-prolyl]thiazolidines as a novel series of highly potent and long-lasting DPP-IV inhibitors. Bioorg Med Chem Lett;17:2618-2621.
7. Haffner C.D., Diaz C.J., Miller A.B., Reid R.A., Madauss K.P., Hassell A., Hanlon M.H., Porter D.J.T., Becherer J.D., Carter L.H. (2008) Pyrrolidinyl pyridone and pyrazinone analogues as potent inhibitors of prolyl oligopeptidase (POP). Bioorg Med Chem Lett;18:4360-4363.
8. Augustyns K.J.L., Lambeir A.M., Borlo M., Meester I.D., Vedernikoval I. (1997) Pyrrolidides: synthesis and structure-activity relationship as inhibitors of dipeptidyl peptidase IV. Eur J Med Chem;32:301-309.
9. Villhauer E.B., Brinkman J.A., Naderi G.B., Burkey B.F., Dunning B.E., Prasad K., Mangold B.L., Russell M.E., Hughes T.E. (2003) 1-[[(3-hydroxy-adamantyl)amino]acetyl]-2-cyano-(S)-pyrrolidine: a potent, selective, and orally bioavailable dipeptidyl peptidase IV inhibitor with antihyperglycemic properties. J Med Chem;46:2774-2789.
10. Brandt I., Joossens J., Chen X., Maes M.B., Scharpe S., Meester I.D., Lambeir A.M. (2005) Inhibition of dipeptidyl-peptidase IV catalyzed peptide truncation by vildagliptin(2S)-{[(3-hydroxyadamantan-1-yl)amino]acetyl}-pyrrolidine-2-carbonitrile). Biochem Pharmacol;70:134-143.
11. Havale S.H., Pal M. (2009) Medicinal chemistry approaches to the inhibition of dipeptidyl peptidase-4 for the treatment of type 2 diabetes. Bioorg Med Chem;17:1783-1802.
12. Hughes T.E., Mone M.D., Russell M.E., Weldon S.C., Villhauer E.B. (1999) NVP-DPP-728 (1-[[[2- [(5-cyanopyridin- 2-yl)amino]ethyl]amino]acetyl]-2-cyano-(S)-pyrrolidine), a slow-binding inhibitor of dipeptidyl peptidase IV. Biochemistry;38:597-603.
13. Augeri D.J., Robl J.A., Betebenner D.A., Magnin D.R., Khanna A., Robertson J.G. (2005) Discovery and preclinical profile of Saxagliptin (BMS-477118): a highly potent, long-acting, orally active dipeptidyl peptidase IV inhibitor for the treatment of type 2 diabetes. J Med Chem;48:5025-5037.
14. Fukushima H., Hiratate A., Takahashi M., Mikami A., Hori M.S., Munetomo E., Kitano K., Chonan S., Saito H., Suzuki A., Takaoka Y., Yamamoto K. (2008) Synthesis and structure-activity relationships of potent 4-fluoro-2-cyanopyrrolidine dipeptidyl peptidase IV inhibitors. Bioorg Med Chem;16:4093-4106.
15. Gupta R.C., Chhipa L., Mandhare A.B., Zambad S.P., Chauthaiwale V., Nadkarni S.S., Dutt C. (2009) Novel N-substituted 4-hydrazino piperidine derivative as a dipeptidyl peptidase IV inhibitor. Bioorg Med Chem Lett;19:5021-5025.
16. Weir G.C., Clore E.E., Zma-Chinsky C.J., Bonnier-weir S. (1981) Islet secretion in new experimental model of non-insulin dependent diabetes. Diabetes Metab Rev;30:590-594.
17. Abeeleh M.A., Ismail Z.B., Alzaben K.R., Halaweh S., Al-Essa M.K., Abuabeeleh J., Alsmady M.M. (2009) Induction of diabetes mellitus in rats using intraperitoneal streptozotocin: a comparison between 2 strains of rats. Eur J Sci Res;32:398-402.
18. Singh S., Sethi S., Khanna V., Benjamin B., Kant R., Sattigeri J., Bansal V.S., Bhatnagar P.K., Davis J.A. (2011) RBx-0597, a potent, selective and slow-binding inhibitor of dipeptidyl peptidase IV for the treatment of type 2 diabetes. Eur J Pharmacol;652:157-163.
19. Yamazaki K., Yasuda N., Inoue T., Nagakura T., Kira K., Shinoda M., Saeki T., Tanaka I. (2006) 7-But-2-ynyl-9-(6-methoxy-pyridin-3-yl)-6-piperazin-1-yl-7, 9-dihydro-purin-8-one is a novel competitive and selective inhibitor of dipeptidyl peptidase IV with an antihyperglycemic activity. J Pharmacol Exp Ther;319:1253-1257.
20. Brooks B.R., Bruccoleri R.E., Olafson B.D., States D.J., Swaminathan S., Karplus M. (1983) CHARMM: a program for macromolecular energy, minimization, and dynamics calculations. J Comb Chem;4:187-217.
21. ® force field. J Comb Chem;13:888-900.
22. Halgren T.H. (1996) Merck molecular force field. I. Basis, form, scope, parameterization, and performance of MMFF94. J Comb Chem;17:490-519.
23. Edmondson S.D., Mastracchio A., Mathvink R.J., He J., Harper B., Park Y.J., Beconi M. et al. (2006) (2S, 3S)- 3-Amino- 4- (3, 3-difluoropyrrolidin-1-yl)- N, N- dimethyl-4- oxo- 2- (4-[1, 2, 4] triazolo[1, 5-a]-pyridin-6-ylphenyl)butanamide: a selective r-amino amide dipeptidyl peptidase IV inhibitor for the treatment of type 2 diabetes. J Med Chem;49:3614-3627.
24. Venkatachalam C.M., Jiang X., Oldfield T., Waldman M. (2003) LigandFit: a novel method for the shape-directed rapid docking of ligands to protein active sites. J Mol Graph Model;21:289-307.
25. Kim D., Wang L., Beconi M., Eiermann G.J., Fisher M.H., He H., Hickey G.J. et al. (2005) (2R)-4-Oxo-4-[3-(Trifluoromethyl)-5, 6-dihydro[1, 2, 4]triazolo[4, 3-a] pyrazin-7(8H)-yl]-1-(2, 4, 5-trifluorophenyl) butan-2-amine: a potent, orally active dipeptidyl peptidase IV inhibitor for the treatment of type 2 diabetes. J Med Chem;48:141-151.